Comparative Pharmacology
Head-to-head clinical analysis: BICILLIN versus DYCILL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BICILLIN versus DYCILL.
BICILLIN vs DYCILL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzathine penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and autolysin inhibition, leading to cell lysis.
Penicillin G benzathine is a slow-release parenteral formulation of penicillin G that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
Benzathine penicillin G 1.2 million units intramuscularly once for early syphilis; 2.4 million units intramuscularly weekly for 3 weeks for late latent syphilis.
250 mg orally every 6 hours or 500 mg orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 0.5–1 hour (prolonged in renal impairment); clinical context: requires probenecid for extended action
0.5-1 hour; prolonged in renal impairment (up to 20 hours in severe cases).
Primarily renal (60–70% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%)
Renal: approx. 60-80% unchanged by glomerular filtration and tubular secretion. Biliary/fecal: minor (less than 10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic